Supplementary Information

Synthesis, *in vitro* Toxicity, and Antitrypanosomal Activity of Arylated and Diarylated Thiazoles

Kelly L. Figueira,[a] Roberson D. Girão, [b] Krislayne N. da Costa,[b] Ana C. R. Barreto,[a] Maria de Nazaré C. Soeiro[b] and Jones Limberger *,[a]

[a]Departamento de Química, Pontifícia Universidade Católica do Rio de Janeiro, Rua Marquês de São Vicente, 225, Gávea, 22451-900 Rio de Janeiro-RJ, Brazil

[b]Laboratório de Biologia Celular, Instituto Osvaldo Cruz, Fiocruz, Pavilhão Cardoso Fontes, Avenida Brasil, 4365, 21040-360 Rio de Janeiro-RJ, Brazil

*e-mail: limberger@puc-rio.br

NMR spectra



Figure S1. ^{1}H NMR (400 MHz, $CDCl_3$) of compound **4a**.



Figure S2. ^{13}C NMR spectrum (APT,100 MHz, $CDCl_3$) of compound **4a**.



Figure S3. ^{1}H NMR (400 MHz, $CDCl_3$) of compound **4b**.



Figure S4. ^{13}C NMR spectrum (APT,100 MHz, $CDCl_3$) of compound **4b**.



Figure S5. ^{1}H NMR (400 MHz, $CDCl_3$) of compound **4c**.



Figure S6. ^{13}C NMR spectrum (APT, 100 MHz, $CDCl_3$) of compound **4c**.



Figure S7. ^{1}H NMR (400 MHz, $CDCl_3$) of compound **4d**.



Figure S8. ^{13}C NMR spectrum (APT,100 MHz, $CDCl_3$) of compound **4d**.



Figure S9. ^{1}H NMR (400 MHz, $CDCl_3$) of compound **4e**.



Figure S10. ^{13}C NMR spectrum (APT, 100 MHz, $CDCl_3$) of compound **4e**.



Figure S11. ^{1}H NMR (400 MHz, DMSO-d_6) of compound **4f**.



Figure S12. ^{13}C NMR spectrum (APT,100 MHz, DMSO-d_6) of compound **4f**.



Figure S13. ^{1}H NMR (400 MHz, $CDCl_3$) of compound **4g**.



Figure S14. ^{13}C NMR spectrum (APT,100 MHz, $CDCl_3$) of compound **4g**.



Figure S15. ^{1}H NMR (400 MHz, DMSO-d_6) of compound **4h**.



Figure S16. ^{13}C NMR spectrum (APT, 100 MHz, DMSO-d_6) of compound **4h**.



Figure S17. ^{1}H NMR (400 MHz, $CDCl_3$) of compound **5**.



Figure S18. ^{13}C NMR spectrum (100 MHz, $CDCl_3$) of compound **5**.



Figure S19. ^{1}H NMR (400 MHz, $CDCl_3$) of compound **6a**.



Figure S20. ^{13}C NMR spectrum (APT,100 MHz, $CDCl_3$) of compound **6a**.



Figure S21. ^{1}H NMR (400 MHz, $CDCl_3$) of compound **6b**.



Figure S22. ^{13}C NMR spectrum (APT, 100 MHz, $CDCl_3$) of compound **6b**.



Figure S23. HRMS (ESI-(+)) spectra of compound **4a**.



Figure S24. HRMS (ESI-(+)) spectra of compound **4b**.



Figure S25. HRMS (ESI-(+)) spectra of compound **4c**.



Figure S26. HRMS (ESI-(+)) spectra of compound **4d**.



Figure S27. HRMS (ESI-(+)) spectra of compound **4e**.



Figure S28. HRMS (ESI-(+)) spectra of compound **4f**.



Figure S29. HRMS (ESI-(+)) spectra of compound **4g**.



Figure S30. HRMS (ESI-(+)) spectra of compound **4h**.



Figure S31. HRMS (ESI-(+)) spectra of compound **5**.



Figure S32. HRMS (ESI-(+)) spectra of compound **6a**.



Figure S33. HRMS (ESI-(+)) spectra of compound **6b**.



Figure S34. Activity of compounds **4c**, **4g** and **4h** against intracellular forms of *T. cruzi* Tulahuen strain.